Answers are grounded in this paper and cite their sources.
Breast cancer remains one of the most commonly diagnosed malignancies worldwide, and developing novel cytotoxic agents that overcome therapeutic resistance remains a major priority in anticancer drug discovery. Building on the pyrrolo[2,3-d]pyrimidine scaffold of tofacitinib, a series of fifteen tofacitinib-derived analogs (5a-n) with aryl substitutions was synthesized and evaluated for cytotoxic activity against Hep-G2, PC-3, and MCF-7 cancer cell lines. Structure-activity relationship (SAR) analysis revealed that para-substitution outperformed ortho-substitution, and among halogens, potency followed the order: Br > Cl > F. The para-bromo analog 5e emerged as the most potent compound against MCF-7 cells (IC50 = 0.99 ± 0.20 µM) and showed strong activity against PC-3 (10.70 ± 0.45 µM). Flow cytometric analysis showed that 5e induced a concentration-dependent response in MCF-7 cells, causing a significant G1 cell cycle arrest that effectively blocks the G1/S transition checkpoint. This block induced programmed cell death, resulting in pronounced late apoptosis (64.5% vs. 1.06% in the control) and a 9.4-fold increase in the Bax/Bcl-2 ratio. To explore a plausible mechanism of action for compound 5e, in silico docking and molecular dynamics simulations against the JAK1 ATP-binding pocket were also performed. Together, these results identify 5e as a promising anticancer lead and provide a validated structural template for linking the pyrrolo[2,3-d]pyrimidine scaffold to cytotoxic and pro-apoptotic activity. When combined with mechanistic and computational evidence, the clear SAR trends based on halogen type and position provide strong support for optimizing the next generation of anticancer agents, especially in the context of therapeutic resistance in breast cancer.
No takes yet. Share an insight, caveat, or question.
Khademi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: